Anzeige
Mehr »
Dienstag, 25.08.2026 - Börsentäglich über 12.000 News
Trommelwirbel! NurExone - jetzt wird es wirklich groß!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWFZ | ISIN: US7530181004 | Ticker-Symbol:
NASDAQ
24.08.26 | 21:59
0,879 US-Dollar
-0,08 % -0,001
1-Jahres-Chart
RANI THERAPEUTICS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
RANI THERAPEUTICS HOLDINGS INC 5-Tage-Chart

Aktuelle News zur RANI THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrH.C. Wainwright bekräftigt Kaufempfehlung für Rani Therapeutics Aktie2
13.08.Rani Therapeutics Holdings, Inc. - 8-K, Current Report1
12.08.Rani Therapeutics wirbt auf Canaccord-Konferenz für orale Biologika3
04.08.Rani Therapeutics appoints Michelle Gilson to board6
04.08.Rani Therapeutics Holdings, Inc. - 8-K, Current Report1
20.07.Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)2
RANI THERAPEUTICS Aktie jetzt für 0€ handeln
15.07.Rani Therapeutics Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans2
15.07.Rani Therapeutics reports positive Phase 1 data for oral obesity drug7
15.07.Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing371RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild...
► Artikel lesen
10.07.China's PegBio Pops on Deal to Develop Oral Formulations for Obesity, Metabolic Drugs With US' Rani Therapeutics2
09.07.Rani Therapeutics partners with PegBio on obesity drugs1
09.07.Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates163~ Collaboration will leverage the RaniPill® platform to explore oral delivery of PegBio's proprietary portfolio of novel obesity and metabolic disease molecules ~ ~ Agreement expands Rani's obesity...
► Artikel lesen
30.06.Rani Therapeutics Holdings, Inc. - 8-K, Current Report-
29.06.Rani Therapeutics CFO Svai Sanford Steps Down, Nicholas Maestas Appointed As Successor1
29.06.Rani Therapeutics Holdings, Inc.: Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer207SAN JOSE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics"; "Rani" or the "Company") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused...
► Artikel lesen
27.05.Rani Therapeutics Holdings, Inc. - 8-K, Current Report2
26.05.Rani Therapeutics raises $20 million in direct offering7
26.05.Rani Therapeutics to raise $20M in registered direct offering5
26.05.Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules2
15.05.Rani Therapeutics CFO Sanford to depart2
Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1